Test Price
4,800 AED✅ Home Collection Available
Lung Cancer Mutation Panel 5 (EGFR, KRAS, BRAF, ALK1, ROS1) in UAE | 4800 AED | DHA Approved Molecular Testing
Executive Summary & Core Metrics
This comprehensive molecular panel provides accurate detection of five key genetic mutations in non-small cell lung cancer (NSCLC), enabling precise targeted therapy guidance and treatment response prediction according to the highest international quality standards.
- ✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited dual technology processing — every result verified by two independent methods (FISH + Sanger Sequencing).
- ✅ Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval — archival FFPE blocks or slides collected from your hospital pathology lab.
- ✅ Clinical Guidance: Complimentary telephonic post‑test clinical guidance for result interpretation with our DHA‑licensed molecular oncology specialists.
- ✅ Insurance: Direct billing verification via WhatsApp at +971 54 548 8731 — most major UAE insurers accepted.
Test Overview & Methodology
The Lung Cancer Mutation Panel 5 is a targeted molecular assay that simultaneously detects clinically actionable variants in EGFR, KRAS, BRAF, ALK1, and ROS1 from formalin‑fixed paraffin‑embedded (FFPE) tumor tissue blocks or archival pathology slides. The assay combines fluorescence in situ hybridization (FISH) for ALK1 and ROS1 rearrangements with Sanger sequencing for EGFR, KRAS, and BRAF point mutations, providing dual orthogonal validation of every reportable finding.
| Feature | DNA Labs UAE Panel | Closest Alternative |
|---|---|---|
| Methodology | FISH (ALK1, ROS1) + Sanger Sequencing (EGFR, KRAS, BRAF) — dual orthogonal validation | Single‑gene PCR or next‑generation sequencing panel (often without simultaneous FISH) |
| Precision / Sensitivity | >99% analytical sensitivity for targeted mutations | Variable; NGS may miss certain structural rearrangements without confirmatory FISH |
| Turnaround Time | 5–7 working days | 7–14 days (NGS with reflex FISH) |
| Regulatory Compliance | ISO 9001:2015, DHA/MOHAP standardised report, complies with UAE PDPL | May lack local accreditation |
| Price (AED) | 4,800 | Often higher for multi‑gene NGS (excluding archival retrieval logistics) |
Physician Insight & Safety Protocols
“Every mutation profile is unique — I always correlate these results with your full clinical picture, imaging, and treatment history. No single biomarker decision should be made in isolation. I encourage you to discuss your report in a dedicated consultation where we translate these findings into a personalised care plan.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011.
⚠️ Critical Medication Advisory
Do not discontinue prescribed targeted therapy without consulting your oncology team.
If you are on EGFR tyrosine kinase inhibitors or ALK/ROS1 inhibitors, altering the dose can cause serious side effects or disease progression. Always coordinate with your treating physician before making any changes.
Patient Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: This test requires an adequate archival tumor tissue sample (FFPE block or slides). Insufficient or necrotic specimens cannot be processed.
- Contraindications: Not suitable for cases of active pregnancy, planned surgery within 7 days, or patients travelling abroad without prior clinical clearance.
- Emergency Signs — seek immediate hospital care: New onset severe chest pain, sudden shortness of breath, coughing up bright red blood (hemoptysis), high fever unresponsive to antipyretics, or confusion.
- Minors: Genetic testing on minors requires explicit parental consent and adherence to UAE child protection regulations.
Patient FAQ & Clinical Guidance
1. What is the Lung Cancer Mutation Panel 5 and how does it guide targeted therapy?
This molecular test identifies actionable EGFR, KRAS, BRAF, ALK1, and ROS1 gene mutations in tumor tissue, enabling precise targeted therapy selection for non‑small cell lung cancer patients. These genes control cell growth; specific alterations predict response to tyrosine kinase inhibitors or ALK/ROS1 inhibitors. Detecting a sensitising EGFR mutation (exon 19 deletion or L858R) or an ALK1/ROS1 rearrangement can make you eligible for first‑line targeted therapy that may significantly improve outcomes.
2. How is the test performed and what preparation is needed?
A small sample of previously collected tumor tissue (FFPE block or slides) is used; no fasting or special preparation is required from you. Our team coordinates with your hospital pathology lab to obtain the archival block. The sample undergoes DNA extraction, Sanger sequencing for point mutations, and FISH for gene rearrangements under strict quality controls. Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
3. How are the results interpreted by my doctor?
Your DHA‑licensed oncologist will correlate the molecular findings with your complete clinical history, imaging studies, and prior treatment record to determine the most appropriate targeted therapy. The report includes actionable mutation status, predicted drug sensitivity, and literature references for each detected alteration. All results are kept strictly confidential in accordance with UAE Personal Data Protection Law (PDPL).
UAE Regulatory & Data Privacy Adherence
This lung cancer panel is performed under ISO 9001:2015 certification (INT/EGQ/2509DA/3139) and fully complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — ensuring patient data privacy and security.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — governing electronic health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability — establishing clinical testing safety and patient consent protocols.
All laboratory operations adhere to the Dubai Healthcare City Authority (DHCA) standards and DHA regulations for diagnostic services.
Clinical & Logistical Metadata
| Test Name | Lung Cancer Mutation Panel 5 (EGFR, KRAS, BRAF, ALK1, ROS1) |
| Price (AED) | 4,800 |
| Turnaround Time | 5–7 working days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue Block or Archival Slides Secure Medical Courier Solid Tissue Specimen Retrieval |
| Methodology Used | FISH (ALK1, ROS1) + Sanger Sequencing (EGFR, KRAS, BRAF) |
| ICD-10-CM Code | C34.9 (Malignant neoplasm of unspecified part of bronchus or lung), Z85.1 (Personal history of malignant neoplasm of bronchus and lung) |
| LOINC Code | 93024-1 (EGFR gene mutations found in Lung cancer specimen by Molecular genetics method) |
| DHA Facility License & Laboratory Address | License No: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Corporate: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians